Ashok Khatri
Harvard University
57 Papers
308 Citations
Ashok Khatri is an academic researcher from Harvard University. The author has contributed to research in topics: Parathyroid hormone & Receptor. The author has an hindex of 24, co-authored 50 publications. Previous affiliations of Ashok Khatri include University of Montpellier & Bristol-Myers Squibb.
Chat about Author
Papers
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.
Ellen Shrock,Ellen Shrock,Eric Fujimura,Eric Fujimura,Tomasz Kula,Tomasz Kula,Richard T. Timms,Richard T. Timms,I-Hsiu Lee,Yumei Leng,Yumei Leng,Matthew L Robinson,Brandon M. Sie,Brandon M. Sie,Mamie Z. Li,Mamie Z. Li,Yuezhou Chen,Jennifer K. Logue,Adam Zuiani,Denise J. McCulloch,Felipe J.N. Lelis,Stephanie A. Henson,Daniel R. Monaco,Meghan Travers,Shaghayegh Habibi,William Clarke,Patrizio Caturegli,Oliver Laeyendecker,Oliver Laeyendecker,Alicja Piechocka-Trocha,Jonathan Z. Li,Ashok Khatri,Helen Y. Chu,Alexandra-Chloé Villani,Kyle R. Kays,Marcia B. Goldberg,Nir Hacohen,Michael R. Filbin,Xu G. Yu,Bruce D. Walker,Bruce D. Walker,Duane R. Wesemann,H. Benjamin Larman,James A. Lederer,Stephen J. Elledge,Stephen J. Elledge +45 more
TL;DR: A systematic characterization of the humoral response to severe acute respiratory system coronavirus 2 (SARS-CoV-2) epitopes has yet to be performed, important for understanding the immunogenicity of the viral proteome and the basis for cross-reactivity with the common-cold coronaviruses.
678
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals
Vivek Naranbhai,Anusha Nathan,C. Kaseke,Cristhian Berríos,Ashok Khatri,Shawn Choi,Matthew A. Getz,Rhoda Tano-Menka,Onosereme Ofoman,Alton C. Gayton,Fernando Senjobe,Zezhou Zhao,K. S. St. Denis,Evan C. Lam,Mary Carrington,Wilfredo F. Garcia-Beltran,Alejandro B. Balazs,Bruce D. Walker,A. John Iafrate,Gaurav D. Gaiha +19 more
TL;DR: In this article , the authors show that T cell responses in individuals with prior infection, vaccination, both prior infection and vaccination, and boosted vaccination are largely preserved to Omicron spike and non-spike proteins.
254
The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals
Marylyn M. Addo,Marcus Altfeld,Eric S. Rosenberg,Robert L. Eldridge,Mary N. Philips,Kathleen Habeeb,Ashok Khatri,Christian Brander,Gregory K. Robbins,Gail P. Mazzara,Philip J. R. Goulder,Bruce D. Walker +11 more
TL;DR: Data indicate that Tat and Rev are frequently targeted by CTL in natural HIV-1 infection and may be important targets for HIV vaccines.
215
CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control
Beatriz Mothe,Beatriz Mothe,Anuska Llano,Javier Ibarrondo,Jennifer Zamarreño,Mattia Schiaulini,Cristina Miranda,Marta Ruiz-Riol,Christoph Berger,M. José Herrero,Eduard Palou,M. Plana,Morgane Rolland,Ashok Khatri,David Heckerman,Florencia Pereyra,Bruce D. Walker,Bruce D. Walker,David B. Weiner,Roger Paredes,Bonaventura Clotet,Barbara K. Felber,George N. Pavlakis,James I. Mullins,Christian Brander +24 more
TL;DR: This data challenge the common belief that Gag-specific T cell responses dominate the virus-specific immunity exclusively in HIV-1 controllers as both groups mounted responses of comparable breadths and magnitudes against the p24 sequence.
Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity
Rohit Sharma,Rohit Sharma,Bryn Reinstadler,Bryn Reinstadler,Kristin Engelstad,Owen S. Skinner,Owen S. Skinner,Erin Stackowitz,Ronald G. Haller,Ronald G. Haller,Clary B. Clish,Kerry A. Pierce,Melissa A. Walker,Melissa A. Walker,Robert Fryer,Devin Oglesbee,Xiangling Mao,Dikoma C. Shungu,Ashok Khatri,Michio Hirano,Darryl C. De Vivo,Vamsi K. Mootha,Vamsi K. Mootha +22 more
TL;DR: In this paper, a panel of organelle function tests related to NADH-reductive stress was defined for classification and monitoring of mt.3243A>G disease, and validated 20 analytes (1 protein, 19 metabolites) that distinguish patients with MELAS from controls.